The observation that osteosarcoma cells frequently express the receptor ERBB2 [95,96] has led to clinical trials assessing the effectiveness of HER2 blocking by trastuzumab (NCT04616560, NCT00005033), even though it did not have any notable effect as a primary metastatic osteosarcoma treatment [97]. This evidence concerns the gene ERBB2 and osteosarcoma.